Author: claimsbot

1. A method for monitoring tissue undergoing ablation, the method comprising:
transmitting microwave energy from a power source to a microwave antenna to form a tissue ablation zone;
monitoring reflected power associated with the microwave antenna to generate a reflected power signal;
calculating a derivative indicative of rise and fall portions of the reflected power signal, wherein when the derivative is taken during a rise portion of the reflected power signal the measured reflected power is assigned a positive value and when the derivative is taken during a fall portion of the reflected power signal the measured reflected power is assigned a negative value, the positive and negative values of the reflected power signal indicating when the microwave antenna and tissue in a near field of the ablation zone are approaching a respective steady-state condition or an impedance match between the microwave antenna and tissue in the near field;
communicating a control signal to the power source when a predetermined reflected power is reached at the microwave antenna; and
adjusting the amount of microwave energy from the power source to the microwave antenna.
2. The method according to claim 1, further comprising:
accessing at least one data look-up table including data pertaining to a control curve varying over time and being representative of at least one electrical parameter associated with the microwave antenna; and
generating a signal when a predetermined threshold value of the at least one electrical parameter is corresponding to the radius of the ablation zone.
3. The method according to claim 2, wherein the at least one electrical parameter is selected from the group consisting of impedance, power, voltage and current.
4. The method according to claim 3, further comprising correlating a reflected signal generated by the power source associated with the microwave antenna during transmission of microwave energy to the microwave antenna when the microwave antenna is in a near field state with the tissue ablation zone.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for treating cancer in a subject comprising administering an effective amount of a composition comprising one or more Thymidylate synthase inhibitor, wherein said one or more Thymidylate synthase inhibitor is a compound, or analog or derivative thereof, selected from:
wherein
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivative;
Hal represents a halogen group producing respective fluoro, chloro, bromo, and iodo; and
L1 and L2 represent linkage bridging the two carbons at the specified position surrounded by parentheses and is C1-C5 alkylene, C2-C5 alkenylene, amidino or ureido type of linkage.
2. The method of claim 1, wherein the one or more Thymidylate synthase inhibitor is selective for cancer cells.
3. The method of claim 1, wherein the one or more Thymidylate synthase inhibitor is a compound selected from the group consisting of:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl;
and derivative and analogs or derivatives of said compounds.
4. The method of claim 1, wherein the method further comprises administering radiation therapy andor at least one additional anti-cancer agent.
5. The method of claim 4, wherein the anti-cancer agent is a chemotherapeutic agent selected from anthracyclines, platinum-based chemotherapy drugs, pyrimidine analogues, biologic agents, kinase inhibitors, alkylating agents, or a combination thereof.
6. The method of claim 5, wherein the chemotherapeutic agent is:
a) an anthracycline selected from doxorubicin, epirubicin, daunorubicin, aclarubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, carminomycin or detorubicin;
b) a platinum-based chemotherapy drug selected from carboplatin, cisplatin, nedaplatin, oxaliplatin, triplatin tetranitrate or satraplatin;
c) a pyrimidine analogue selected from 5-fluorouracil (5-FU), cytarabine or floxuridine;
d) an alkylating agent selected from cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan and bendamustine; nitrosourea compounds selected from carmustine, lomustine, semustine and streptozotocin; busulfan; dacarbazine; procarbazine; altretamine; mitozolomide; or temozolomi de;
e) biologic agents selected from epotin, opreleukin, filgrastim, pegfilgrastim, rituximab, trastuzumab, or aldesleukin; or
f) a tyrosine kinase inhibitor selected from the group consisting of sorafenib, sunitinib and imatini b.
7. The method of claim 1, wherein the cancer is acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer, or breast cancer.
8. The method of claim 7, wherein the cancer is triple negative breast cancer.
9. The method of claim 1, wherein the subject is human.
10. A method of reducing the growth, proliferation, or survival of a neoplastic cell comprising contacting the cell with a composition comprising an effective amount of one or more Thymidylate synthase inhibitor compound selected from the group consisting of:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl;

and derivative and analogs or derivatives of said compounds.
11. The method of claim 10, wherein the one or more Thymidylate synthase inhibitor compound is selective for neoplastic cells.
12. The method of claim 10, wherein the one or more Thymidylate synthase inhibitor compound is selected from the group consisting of:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, suiphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl;
and derivative and analogs or derivatives of said compounds.
13. The method of claim 12, wherein the method further comprises administering radiation therapy andor at least one additional anti-cancer agent.
14. The method of claim 13, wherein the anti-cancer agent is a chemotherapeutic agent selected from anthracyclines, platinum-based chemotherapy drugs, pyrimidine analogues, biologic agents, kinase inhibitors, alkylating agents, or a combination thereof.
15. The method of claim 14, wherein the chemotherapeutic agent is:
a) an anthracycline selected from doxorubicin, epirubicin, daunorubicin, aclarubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, carminomycin or detorubicin;
b) a platinum-based chemotherapy drug selected from carboplatin, cisplatin, nedaplatin, oxaliplatin, triplatin tetranitrate or satraplatin;
c) a pyrimidine analogue selected from 5-fluorouracil (5-FU), cytarabine or floxuridine;
d) an alkylating agent selected from cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan and bendamustine; nitrosourea compounds selected from carmustine, lomustine, semustine and streptozotocin; busulfan; dacarbazine; procarbazine; altretamine; mitozolomide; or temozolomide;
e) biologic agents selected from epotin, opreleukin, filgrastim, pegfilgrastim, rituximab, trastuzumab, or aldesleukin; or
f) a tyrosine kinase inhibitor selected from the group consisting of sorafenib, sunitinib and imatinib.
16. The method of claim 10, wherein the cancer is acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer, or breast cancer.
17. The method of claim 16, wherein the cancer is triple negative breast cancer.
18. The method of claim 10, wherein the subject is human.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, one or more compound selected from the group consisting of:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl;

and derivative and analogs or derivatives of said compounds and, optionally, a chemotherapeutic agent.
20. The pharmaceutical composition of claim 19, wherein the compound is selected from:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl;

and derivative and analogs or derivatives of said compounds.
21. The pharmaceutical composition of claim 20, wherein the chemotherapeutic agent selected from anthracyclines, platinum-based chemotherapy drugs, pyrimidine analogues, kinase inhibitors, alkylating agents, or a combination thereof.
22. The pharmaceutical composition of claim 20, wherein the chemotherapeutic agent is:
a) an anthracycline selected from doxorubicin, epirubicin, daunorubicin, aclarubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, carminomycin or detorubicin;
b) a platinum-based chemotherapy drug selected from carboplatin, cisplatin, nedaplatin, oxaliplatin, triplatin tetranitrate or satraplatin;
c) a pyrimidine analogue selected from 5-fluorouracil (5-fu), cytarabine or floxuridine;
d) an alkylating agent selected from cyclophosphamide, chlorambucil, uramustine, ifosfamide, melphalan and bendamustine; nitrosourea compounds selected from carmustine, lomustine, semustine and streptozotocin; busulfan; dacarbazine; procarbazine; altretamine; mitozolomide; or temozolomide;
e) biologic agents selected from epotin, opreleukin, filgrastim, pegfilgrastim, rituximab, trastuzumab, or aldesleukin; or
f) a tyrosine kinase inhibitor selected from the group consisting of sorafenib, sunitinib and imatinib.
23. A method of treating a disease or disorder comprising the administering, to a subject having a disease or disorder responsive to inhibition of Thymidylate synthase, a therapeutically effective amount of one or more compound selected from the group consisting of:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl;
and derivative and analogs or derivatives of said compounds.
24. The method of claim 23, wherein said disease or disorder is associated with excessive activity of Thymidylate synthase.
25. The method of claim 23, wherein said disease or disorder is selected from the group consisting of Paget’s disease of the bone, Paget’s disease of the breast, and extramammary Paget’s disease.
26-30. (canceled)
31. A Thymidylate synthase inhibitor of formula:
wherein:
R1, R3, R4 and R5 are independently, a hydrogen atom, methyl, C1-C5 branched or unbranched alkyl, amino, nitro, amidino, sulpho, sulphonamido, carboxy, cyano, phenyl, thienyl, pyrril, pyrazolyl, imidazolyl, isoxazyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, quinazolyl, pyridyl, pyrimidyl group, C1-C5 alkenyl, C1-C5 alkylamino, C2-C10 dialkylamino, hydroxy C1-C5 alkyl, carbonyl, C3-C7 cycloalkyl or trifluoromethyl group;
R2 is a hydrogen atom, C1-C5 alkyl, hydroxy, amino, nitro, sulpho, sulphonamido, carboxy, or cyano group;
X is a carbon, nitrogen, oxygen or sulphur atom at the indicated position, producing respective alkyl, alkylamino, alkoxy, sulphaalkyl derivatives;
Y is a carbon, nitrogen or oxygen atom at the indicated position, producing respective alkyl alkylamino, alkoxy derivatives;
and derivative and analogs or derivatives of said compounds.

1. A seed comprising at least one set of the chromosomes of maize inbred line PH907, representative seed of said line having been deposited under ATCC Accession No. PTA-6361, wherein said chromosomes comprise all of the alleles of inbred line PH907 at the SSR loci listed in Table 2.
2. A maize plant produced by growing the seed of claim 1.
3. A maize plant part of the maize plant of claim 2.
4. The seed of claim 1, wherein said seed is an F1 hybrid maize seed produced by crossing a plant of maize inbred line PH907 with a different maize plant and harvesting the resultant F1 hybrid maize seed.
5. A maize plant produced by growing the F1 hybrid maize seed of claim 4.
6. A maize plant part of the maize plant of claim 5.
7. An F1 hybrid maize seed comprising an inbred maize plant cell of inbred maize line PH907, representative seed of said line having been deposited under ATCC Accession No. PTA-6361.
8. A maize plant produced by growing the F1 hybrid maize seed of claim 7.
9. The F1 hybrid maize seed of claim 7 wherein the inbred maize plant cell comprises two sets of chromosomes of maize inbred line PH907, wherein said chromosomes comprise all of the alleles of inbred line PH907 at the SSR loci listed in Table 2.
10. A maize plant produced by growing the F1 hybrid maize seed of claim 9.
11. A process of introducing a desired trait into maize inbred line PH907 comprising:
(a) crossing PH907 plants grown from PH907 seed, representative seed of which has been deposited under ATCC Accession No: PTA-6361, with plants of another maize line that comprise a desired trait to produce F1 progeny plants, wherein the desired trait is selected from the group consisting of waxy starch, male sterility, herbicide resistance, insect resistance, bacterial disease resistance, fungal disease resistance, and viral disease resistance;
(b) selecting F1 progeny plants that have the desired trait to produce selected F1 progeny plants;
(c) crossing the selected progeny plants with the PH907 plants to produce backcross progeny plants;
(d) selecting for backcross progeny plants that have the desired trait and the alleles of inbred line PH907 at the SSR loci listed in Table 2 to produce selected backcross progeny plants; and
(e) repeating steps (c) and (d) to produce backcross progeny plants that comprise the desired trait and comprise at least 95% of the alleles of inbred line PH907 at the SSR loci listed in Table 2.
12. A plant produced by the process of claim 11, wherein the plant comprises at least 95% of the alleles of inbred line PH907 at the SSR loci listed in Table 2.
13. A maize plant having all the physiological and morphological characteristics of inbred line PH907, wherein a sample of the seed of inbred line PH907 was deposited under ATCC Accession Number PTA-6361.
14. A process of producing maize seed, comprising crossing a first parent maize plant with a second parent maize plant, wherein one or both of the first or the second parent maize plants is the plant of claim 13, and harvesting the resultant seed.
15. The maize seed produced by the process of claim 14.
16. The maize seed of claim 15, wherein the maize seed is hybrid seed.
17. A hybrid maize plant, or its parts, produced by growing said hybrid seed of claim 16.
18. The maize plant of claim 13, further comprising an SSR profile in accordance with the profile shown in Table 2.
19. A cell of the maize plant of claim 13.
20. The cell of claim 19, wherein said cell is further defined as having an SSR profile in accordance with the profile shown in Table 2.
21. A seed comprising the cell of claim 19.
22. The maize plant of claim 13, further defined as having a genome comprising a single locus conversion.
23. The maize plant of claim 22, wherein the single locus was stably inserted into a maize genome by transformation.
24. The maize plant of claim 22, wherein the locus is selected from the group consisting of a dominant allele and a recessive allele.
25. The maize plant of claim 22, wherein the locus confers a trait selected from the group consisting of herbicide tolerance; insect resistance; resistance to bacterial, fungal, nematode or viral disease; waxy starch; male sterility and restoration of male fertility.
26. The maize plant of claim 13, wherein said plant is further defined as comprising a gene conferring male sterility.
27. The maize plant of claim 13, wherein said plant is further defined as comprising a transgene conferring a trait selected from the group consisting of male sterility, herbicide resistance, insect resistance, and disease resistance.
28. A method of producing a maize plant comprising the steps of:
(a) growing a progeny plant produced by crossing the plant of claim 13 with a second maize plant;
(b) crossing the progeny plant with itself or a different plant to produce a seed of a progeny plant of a subsequent generation;
(c) growing a progeny plant of a subsequent generation from said seed and crossing the progeny plant of a subsequent generation with itself or a different plant; and
(d) repeating steps (b) and (c) for an additional 0-5 generations to produce a maize plant.
29. The method of claim 28 wherein the produced maize plant is an inbred maize plant.
30. The method of claim 29, further comprising the step of crossing the inbred maize plant with a second, distinct inbred maize plant to produce an F1 hybrid maize plant.
31. A method for developing a second maize plant in a maize plant breeding program comprising applying plant breeding techniques to a first maize plant, or parts thereof, wherein said first maize plant is the maize plant of claim 13, and wherein application of said techniques results in development of said second maize plant.
32. The method for developing a maize plant in a maize plant breeding program of claim 31 wherein plant breeding techniques are selected from the group consisting of recurrent selection, backcrossing, pedigree breeding, restriction fragment length polymorphism enhanced selection, genetic marker enhanced selection, and transformation.
33. A method of plant breeding comprising the steps of:
(a) obtaining a molecular marker profile of maize inbred line PH907, representative seed of said line having been deposited under ATCC Accession No. PTA-6361;
(b) obtaining an F1 hybrid seed for which the maize plant of claim 13 is a parent;
(c) crossing a plant grown from the F1 hybrid seed with a different maize plant; and
(d) selecting progeny that possess said molecular marker profile of PH907.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A method of providing information about at least one item in response to a request from a requester, the request related to a proximity of the requestor to the at least one item, the method comprising the steps of:
receiving a request from the requester related to the at least one item at a server’s computer;
retrieving data in the server computer, the data comprising the latitudes and longitudes of locations of the at least one item;
determining the latitude and longitude of the position of the requestor;
computing distances between the locations of the at least one item and the position of the requestor;
determining a desired proximity range for the requestor; and
providing information to the requestor limited to the at least one item located within the desired proximity range.
2. The method of claim 1 further including the steps of:
sorting the distances from the locations of the at least one item and the position of the requestor by said server computer; and
providing to the requester the information related to the at least one item with the at least one item closest to the requestor listed first.
3. The method of claim 1 including the step of deriving the latitudes and longitudes for the at least one item from at least one geographical chart.
4. The method of claim 1 including the step of deriving the latitudes and longitudes for the at least one item from at least one global positioning system receiver.
5. A system for providing information from a server in response to a request from a requester, said request related to an at least one item including the location of the at least one item, the system comprising:
a server computer;
a network connection available to said server computer whereby information may be transmitted between said server computer and a computer of the requester;
a database connected to said server computer, said database containing said at least one item’s location, said database further comprising related information taken from the group of related information including times of occurrence, availabilities and costs for said at least one item;
a means to determine the requestor’s position;
a distance computation program available in said server computer wherein distance information from said at least one item’s location and the requestor’s position may be computed; and
an output available from said server computer to said requestor providing related information related for said at least one item located within a desired proximity from the requestor’s position.
6. The system of claim 5 wherein said location of said at least one item and said position of the requester are in the form of latitudes and longitudes.
7. The system of claim 6 wherein said means to determine the requestor’s position includes calculating the requestor’s position from street address information provided by the requestor.
8. The system of claim 7 wherein a plurality of items are included in said output and said output is sorted with items closer to the requestor listed first.
9. The system of claim 8 wherein said related information is matchable to a request from the requestor so that only items which have related information matching the requestor’s request are included in said output.
10. The system of claim 9 wherein said request includes a proximity limitation from the requestor and only items which are within the proximity limitation are included in said output.
11. A method for identifying availability of a desired item within a desired proximity of a user, the method including the steps of:
entering names of a plurality of items into a searchable database, at least a portion of the items taken from a group of items including activities, sporting events, non-sporting events and facilities available for reservation;
entering at least one descriptive characteristic into the database associated with each item in the database;
entering a location of each item into the database;
receiving a query from a user about availability of items that have at least one characteristic matching a characteristic specified in the query;
determining a position of the user;
determining a desired proximity range;
calculating a distance from the position of the user to at least the items that have at least one characteristic matching a characteristic specified in the query; and
outputting to the user at least one item matching at least one characteristic specified in the query and located within the desired proximity.
12. The method of claim 11 wherein said at least one descriptive characteristic includes at least one characteristic taken from a group of characteristics including time of item availability, date of item availability, type of item and cost associated with item.
13. The method of claim 12 wherein each said item within said database includes each of the descriptive characteristics included in the group of descriptive characteristics provided within the database for each of the items contained within the database.
14. The method of claim 11 wherein said entering a location step and said determining a position step includes identifying a latitude and a longitude of the location of each item and a latitude and a longitude of the position of the user, such that distance calculations can be made based on the latitudes and longitudes of the items and the user.
15. The method of claim 14 wherein said calculating step includes the steps of determining a difference in the latitude of at least one of the items and a latitude of the user and a difference between a longitude of at least one of the items and a longitude of the user; and
deriving the distance between the location of at least one of the items and the position of the user by taking the square root of the sum of the square of the difference between the latitudes of at least one of the items and the user and the square of the difference between the longitude of at least one of the items and the user.
16. The method of claim 11 wherein said determining a position of the user step includes the steps of entering information within the database about the user including the user’s position; and
calling up the user’s position information when the user is identified.
17. The method of claim 11 wherein said determining a position of the user step includes the steps of identifying a street address of the user and correlating the street address of the user with a latitude and longitude of the user.
18. The method of claim 11 wherein said determining a desired proximity range step includes the step of allowing the user to select the proximity range and include this proximity range within the query of said receiving step.
19. The method of claim 11 wherein said determining a desired proximity range step is preselected as a fixed distance within the database.
20. The method of claim 11 including the further step of sorting the items of said outputting step such that closest items appear first and more distant items appear later.